News
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share of Class
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 5, 2022, following the release of its first quarter
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today the publication of a peer-reviewed article
DGAP-News: MicroVision Inc.: MicroVision to Announce First Quarter 2022 Results on April 27, 2022
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2022 financial results on Wednesday, May 4, 2022, before the open of the US financial markets. Clovis’ senior management will
STAAR Surgical to Report First Quarter Results on May 4, 2022
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of its new flagship facility in the heart of downtown Portsmouth, New Hampshire
Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2022 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April
Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2022 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April
Simulations Plus to Present at the Berenberg Discover AI Seminar
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be
Agilent Joins the National Institute for Innovation in Manufacturing to Advance Biomanufacturing
Agilent Technologies Inc. (NYSE: A) announced that it has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL). Membership in NIIMBL demonstrates
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN)
Humana’s Impact Report Focuses on Building Trust and Transparency in Journey to Health Equity
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, released its 2021 Impact Report, which highlights the company’s continued commitment to its Environment
Acadia Healthcare Announces Date for First Quarter 2022 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its first quarter 2022 results on Tuesday, May 3, 2022, after the close of the market. Acadia will conduct a
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster
Humana Expands National Commitment to Affordable Housing With Additional $25 Million Investment
As part of its national commitment to improve housing stability for vulnerable members and communities, Humana Inc. (NYSE: HUM) today announced an additional $25 million investment in three
Quidel to Hold Fiscal First Quarter 2022 Financial Results Conference Call on May 4th, 2022
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2022
Humana Throws the First Pitch Event to Connect Minority-Owned Businesses to Top Humana Suppliers
The Supplier Diversity Team of Humana Inc. (NYSE: HUM) hosted the First Pitch, a virtual forum where participants from the Humana Mentor Protégé Program had the opportunity to pitch their business
Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the Commercial Arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has exercised its
DGAP-News: Evotec SE veröffentlicht Ergebnisse des Geschäftsjahres 2021: 'Setting the Pace' auf der 'data-driven R&D Autobahn to Cures'
DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
Regulatory News:
NANOBOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for
Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including